Sufyan Said, MD
Endocrinology, Diabetes & Metabolism · Springfield, ILNPI 1982885257
Payments from drug & device makers
Across 111 payments — averaging $136.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$13K
- Novo Nordisk$285
- Amgen$234
- Novartis$182
- Corcept Therapeutics$158
- Insulet Corporation$131
- plus $1K from 31 others
What the payments were for
- Travel & lodging$1,28634%
- Food & beverage$2,36463%
- Education$973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $12,965 |
| Novo Nordisk | 10 | $285 |
| Amgen | 13 | $234 |
| Novartis | 10 | $182 |
| Corcept Therapeutics | 4 | $158 |
| Insulet Corporation | 5 | $131 |
| Boehringer Ingelheim | 6 | $127 |
| AbbVie | 7 | $115 |
| Calliditas Therapeutics US Inc. | 5 | $114 |
| Abbott | 4 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $78 |
| Radius Health, Inc. | 5 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Medtronic | 1 | $30 |
| Organon | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Sandoz | 1 | $24 |
| Merck | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Valeritas, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $14 |
| BETA Bionics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$105
How this compares
$15,203 in reported general payments places this provider in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 445 | $615,663 |
| TrulicityDulaglutide | 469 | $560,952 |
| JardianceEmpagliflozin | 364 | $439,097 |
| FarxigaDapagliflozin Propanediol | 79 | $77,880 |
| Teriparatide | 29 | $76,156 |
| JanuviaSitagliptin Phosphate | 59 | $74,979 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 128 | $72,346 |
| Humalog Kwikpen U-100Insulin Lispro | 185 | $67,975 |
| MounjaroTirzepatide | 43 | $62,879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 362 | $58,292 |
| Novolog FlexpenInsulin Aspart | 203 | $56,552 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $40,536 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $37,593 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $37,242 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $31,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $42 | $633,766548 claims |
| Novo NordiskOzempic, Novolog | $285 | $625,961487 claims |
| Boehringer IngelheimJardiance | $127 | $439,097364 claims |
| AstraZenecaFarxiga | $15 | $77,88079 claims |
| MerckJanuvia | $24 | $74,97959 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus, Admelog | $78 | $41,409103 claims |
| AbbVieSynthroid | $115 | $9,14684 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Springfield
- Marina RussoSpringfield$220K
- Gabriel UwaifoSpringfield$195K
- Kevin HazardSpringfield$44K
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.